Table 4.
Univariate and multivariate analysis of prophylactic use of low-dose interleukin-2 on allogeneic stem cell transplantation outcomes.
| Univariate analysis |
Multivariate analysis |
|||||
|---|---|---|---|---|---|---|
| Covariate | HR | 95% CI | p | HR | 95% CI | p |
| Acute GVHD | ||||||
| HLA mismatch | 4.5 | 2.3–8.8 | <0.0001 | 5.1 | 2.6–10.2 | <0.0001 |
| CMV infection | 2.7 | 0.9–7.5 | 0.063 | |||
| Infused lymphocyte/kg recipient weight | 1.0 | 1.0–1.1 | 0.02 | |||
| Infused CD3+ cells/kg recipient weight | 1.01 | 1.0–1.01 | 0.021 | |||
| Infused CD4+ cells/kg recipient weight | 1.01 | 1 to 1.02 | 0.047 | |||
| Infused CD8+ cells/kg recipient weight | 1.01 | 1.0–1.02 | 0.02 | 1.01 | 1.0–1.02 | 0.008 |
| Infused CD14+ cells/kg recipient weight | 1.01 | 1.0–1.01 | 0.008 | |||
| Overall chronic GVHD | ||||||
| Donor sex (female vs. male) | 2.1 | 1.2–3.7 | 0.011 | 2.1 | 1.2–3.7 | 0.012 |
| MRD-positive | 1.5 | 1.0–2.2 | 0.06 | 1.9 | 1.0–3.5 | 0.045 |
| Moderate-to-severe chronic GVHD | ||||||
| Donor sex (female vs. male) | 2.5 | 1.3–4.9 | 0.009 | 2.4 | 1.2–4.8 | 0.011 |
| Donor–recipient sex mismatch | 1.3 | 1.0–1.7 | 0.088 | |||
| CMV infection | 0.5 | 0.2–1.0 | 0.063 | |||
| MRD-positive | 1.5 | 0.9–2.4 | 0.089 | |||
| Presence or absence of prophylactic IL-2 | 0.5 | 0.3–0.9 | 0.027 | 0.5 | 0.3–0.9 | 0.033 |
| MRD | ||||||
| Donor–recipient sex mismatch | 0.4 | 0.1–1.0 | 0.051 | |||
| Presence or absence of prophylactic IL-2 | 0.4 | 0.2–1.0 | 0.049 | 3.3 | 1.2–9.1 | 0.022 |
| Infused CD34+ cells/kg recipient weight | 1.2 | 1.0–1.5 | 0.065 | |||
| Relapse | ||||||
| Donor–recipient sex mismatch | 0.2 | 0–0.9 | 0.034 | |||
| MRD-positive | 2.5 | 1.2–5.2 | 0.019 | 8.1 | 2.4–27.9 | 0.001 |
| Moderate-to-severe cGVHD | 0.2 | 0–0.8 | 0.027 | 0.2 | 0–0.8 | 0.028 |
| Non-relapse mortality | ||||||
| Presence or absence of prophylactic IL-2 | 0.2 | 0–1.2 | 0.076 | 0.2 | 0–1.2 | 0.076 |
| GPFS | ||||||
| Donor sex (female vs. male) | 2.1 | 1.2–3.7 | 0.014 | |||
| DLI | 1.8 | 0.9–3.5 | 0.085 | |||
| Presence or absence of prophylactic IL-2 | 0.6 | 0.3–1.0 | 0.052 | |||
| MRD-positive | 1.7 | 1.2–2.5 | 0.002 | 1.8 | 1.2–2.6 | 0.002 |
| Infused lymphocyte/kg recipient weight | 0.9 | 0.9–1.0 | 0.064 | |||
| LFS | ||||||
| CMV infection | 2.0 | 0.9–4.7 | 0.099 | 2.2 | 0.9–5.0 | 0.073 |
| MRD-positive | 2.4 | 1.0–5.7 | 0.04 | 2.6 | 1.1–6.1 | 0.029 |
Note: All variables were first included in the univariate analysis; only variables with p < 0.1 were included in the Cox proportional hazards regression model.
Abbreviations: DLI, donor lymphocyte infusion; GVHD graft-versus-host disease; GPFS, GVHD progression free survival; HR, hazard ratio; LFS, leukemia-free survival; MRD, minimal residual disease; NRM, non-relapse mortality.